Denmark allows unapproved pill for at-risk Covid-19 patients in line with EMA advice

The European Medicines Agency has issued advice pertaining to the emergency use of the unapproved MSD's Covid-19 tablet treatment, Lagevrio (molnupiravir) – the Danish Health Authority is now allowing treatment with the drug in Denmark.

Photo: MSD / PR

The Danish Health Authority is now allowing Danish doctors to use MSD's tablet treatment, Lagevrio (molnupiravir), to treat Covid-19 patients, despite the drug having yet to be formally approved by the European Medicines Agency (EMA), the Danish authority reports in a press release.

"We recommend the tablet treatment because we have assessed that the benefits outweigh the risks for patients risking severe Covid-19 infections. We expect the treatment will contribute to reducing the number of at-risk patients being hospitalized," MD at Danish Health Authority Kirstine Moll Harboe says in the press release, adding:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs